Decades after the discovery of natural killer (NK) cells, their developmental pathways in mice and humans have not yet been completely deciphered. Accumulating evidence indicates that NK cells can develop in multiple tissues throughout the body. Moreover, detailed and comprehensive models of NK cell development were proposed soon after the turn of the century. However, with the recent identification and characterization of other subtypes of innate lymphoid cells (ILCs), which show some overlapping functional and phenotypic features with NK cell developmental intermediates, the distinct stages through which human NK cells develop from early hematopoietic progenitor cells remain unclear. Thus, there is a need to reassess and refine older models of NK cell development in the context of new data and in the era of ILCs. Our group has focused on elucidating the developmental pathway of human NK cells in secondary lymphoid tissues (SLTs), including tonsils and lymph nodes. Here, we provide an update of recent progress that has been made with regard to human NK cell development in SLTs, and we discuss these new findings in the context of contemporary models of ILC development.
iNtrODUctiON Natural killer (NK) cells belong to the family of innate lymphoid cells (ILCs) whose common features include reliance on the transcription factor ID2 for development and rapid elaboration of effector function in response to microbial products, cytokine stimulation, and contact with other leukocytes (1) . ILCs share phenotypic and functional features with T cells, yet, ILCs lack expression of markers specific for other leukocytes, including antigen-specific T and B cell receptors (i.e., CD3/ TCR and CD19/BCR). In 2013, Spits et al. published a proposal for ILC nomenclature and classification, including the designation of three major groups according to functional and phenotypic characteristics (2) . Group 1 ILCs, which express the transcription factor T-BET and produce the T helper cell type 1 (Th1)-associated cytokine interferon gamma (IFN-γ), include NK cells as well as functionally distinct "ILC1s. " NK cells are unique in their expression of the transcription factor EOMES and in their ability to recognize and destroy virally infected and malignantly transformed cells that have downregulated major histocompatibility (MHC) class I molecules and/or upregulated stress-induced molecules (3, 4) . Group 2 ILCs or "ILC2s" produce Th2-associated cytokines, such as interleukin (IL)-5 and IL-13; they express the transcription factors BCL11B, GATA-3, and RORα; and they are involved in many processes, including fat metabolism, allergy, and protection against parasites (5) . Group 3 ILCs share features with Th17 cells, including expression of the transcription factors AHR and RORγt and production of IL-17 and IL-22. Group 3 ILCs consist of "ILC3s" as well as lymphoid tissue inducer cells whose roles include the formation and restoration of lymphoid tissues following infection (6) . We refer the readers to other excellent comprehensive reviews exploring the development, transcriptional regulation, and diverse roles of ILCs in physiology and disease (1, (7) (8) (9) (10) (11) (12) .
As mentioned above, ILCs are identified as "lineage" (Lin) negative lymphocytes, lacking expression of surface markers more specifically expressed on T cells (CD3, CD5, TCR), B cells (CD19, CD20, BCR), myelomonocytic cells (CD14, CD15, CD36), and dendritic cells (DCs) (CD116, CD123, CD303). In humans, all non-NK ILCs express CD127 (IL-7Rα) and CD161 (NKRP1A) (13-16), and they may be further distinguished according to the expression of other subset-associated surface antigens including CXCR3, CD294 (CRTH2), and CD117 (c-Kit) for ILC1s, ILC2s, and ILC3s, respectively (10, 17) . Human NK cells can also express the pan-ILC markers CD127 and CD161 (18) (19) (20) , but NK cells are typically distinguished by their surface expression of CD16 (FcγRIIIA), CD94/NKG2 heterodimers, killer immunoglobulin-like receptors (KIRs), NKG2D, and NKp80 (21) . Two subsets of human peripheral blood (PB) NK cells can be distinguished according to their relative expression of the pan-NK cell surface marker, CD56 (NCAM-1): "CD56 bright " and "CD56 dim " (22, 23) . CD56 bright human NK cells express high levels of CD62L (l-selectin) and CD94 but absent or low levels of CD16 and KIRs; they predominate in secondary lymphoid tissues (SLTs) such as lymph nodes (LNs) and tonsils; they show low baseline perforin expression and cytotoxic activity ex vivo; and they rapidly produce cytokines, including IFN-γ, following stimulation by monocyte-derived cytokines ("monokines"), such as IL-12, IL-15, and IL-18 (22) . In contrast, CD56 dim NK cells are CD16 hi and express more KIRs but less CD94 and CD62L; they predominate in PB; they show high baseline perforin expression and cytotoxicity against MHC class I negative target cells; and they preferentially produce cytokines in response to direct target cell interactions rather than via monokine stimulation (3) . While the developmental relationship between these human NK cell subsets has not been definitively established, evidence suggests that CD56 bright NK cells represent immediate physiologic precursors of CD56 dim NK cells (19, (24) (25) (26) (27) (28) (29) . Alternative hypotheses include that CD56 bright NK cells represent activated NK cells in vivo and/or that PB NK cell subsets derive from distinct hematopoietic progenitor cells (HPCs) and developmental pathways (22, (30) (31) (32) (33) . Recent published data from Dunbar and colleagues suggest that the latter may be the case in rhesus macaques (34) .
HUMAN NK ceLL DeveLOPMeNt iN sLts
Human NK cells were originally thought to develop strictly within the bone marrow (BM) (3, 35) . This notion was supported by the observation that Lin − CD56 + cytotoxic NK cells can be generated in vitro following culture of purified human BM CD34
+ HPCs with either BM-derived stroma or with IL-15, which can be produced by stroma (36, 37 Figure 1A ) (38) (39) (40) (41) (42) . Similar NKDIs have also been identified in the thymus, liver, and uterus (43) (44) (45) . Thus, human NK cell development is likely not restricted to SLTs (46) . In 2006, five putative stages of human SLT NK cell development were described according to the differential expression of CD34, CD117, CD94, and CD16 (41, 47, 48 
receNt ADvANces iN OUr UNDerstANDiNG OF HUMAN NKDis
Continued ex vivo phenotypic and functional characterization of the aforementioned five putative NKDI populations in 
sLts). (A) Ex vivo immunophenotypic analyses of CD3
+ cells (top row, left plots), CD19 + cells (top row, right plots), and Lin − CD56 + cells (bottom row) in the indicated tissues demonstrate how immature T, B, and NK cell developmental intermediates (designated by the red circles and ovals) are naturally enriched in the thymus, bone marrow, and SLTs, respectively. Of note, the SLT populations designated by the red circles in the bottom row also likely contain some ILC3s, which can express CD56 (14) . The red arrows in the bottom row highlight the relative enrichment of stage 4b CD56 bright NKp80 + CD16 − NK cells in SLTs. (B) Immunophenotypic analysis of Lin − ILCs in human tonsil demonstrating the two-way patterns of CD34, CD117, CD94, NKp80, and CD16 expression as they relate to one another. The red arrows depict the putative directions of progressive NK cell development in SLTs. (c) Schematic representation of the proposed stages of human NK cell development in SLTs. The stages are defined according to the differential expression of CD34, CD117, interleukin (IL)-1R1, CD94, NKp80, CD16, and CD57, and the red lines underline the surface antigen changes that define each stage transition. Although not depicted, it is noted that CD56 expression is first detected at stage 2b (heterogeneous), peaks at stage 4b (CD56 bright ), and then decreases to the level of most peripheral blood NK cells at stage 6 (CD56 dim ). Also not depicted is killer immunoglobulin-like receptor expression, which is first detected within stage 4b in SLTs (40) . (56) . Within the stage 3/ILC3 population in human SLTs, there is marked heterogeneity with regards to the expression of numerous surface markers, including CD7, CD56, CD62L, HLA-DR, and NKp44 (14, 41, 57, 58) . The significance of this heterogeneity is largely unknown, although it was shown that NKp44 expression closely correlates with IL-22 production ex vivo (53, 58) .
Last, in a recent study by Freud and colleagues, the SLT stage 4 population, defined as Lin
, was shown to contain two functionally distinct subsets according to expression of the surface activating C-type lectin-like receptor, NKp80 (40) , which is expressed on most if not all PB NK cells in healthy humans (59) . Freud et al. described these SLT stage 4 subsets as stage "4a" (NKp80 − ) and stage "4b" (NKp80 + ), and they demonstrated that only the stage 4b subset is capable of IFN-γ production and perforin-dependent cellular cytotoxicity ex vivo (40) . Consistent with these functional data, the surface expression of NKp80 among total SLT ILCs closely correlates with intracellular expression of T-BET, EOMES, and perforin. In contrast to stage 4b cells, stage 4a cells, which express CD94/ NKG2A, lack the aforementioned functional and phenotypic features associated with mature NK cells and rather show a stage 3/ILC3-like profile including expression of CD117, CD127, IL-1R1, AHR, RORγt, and IL-22 (40) . Following co-culture with allogeneic monocyte-derived DCs or transplantation into NSG mice treated with IL-15, purified SLT stage 4a cells gave rise to functional NK cells including some that were NKp80 
MODeLiNG HUMAN NK ceLL DeveLOPMeNt iN tHe cONteXt AND erA OF iLcs
Collectively, these recently published data described above support an updated linear model of human NK cell development ( Figure 1C) (19, 24, 26) . Despite the accumulating evidence in support of this proposed model, it is likely that other pathways of human NK cell development exist in vivo and potentially account for the marked diversity among tissue-resident NK cells (62) (63) (64) . For example, Renoux et al. recently described a putative lineage committed NK cell progenitor (NKP) population in human (65) are not yet known. In addition, the relationship and possible distinction between human stage 3 natural killer (NK) cell precursors and ILC3s is also not yet clear. In the diagram to the right depicting human ILC development, the labels ILC3P (for ILC3 progenitor), ILC2P (for ILC2 progenitor), and ILC1P (for ILC1 progenitor) are shown in parentheses to convey that these are theoretical populations that have not been identified. CILP, common innate lymphoid progenitor; CHILP, common helper innate lymphoid progenitor. (65) . Given that this NKP is only partially CD117 + and reportedly lacks detectable expression of CD161 and CD127, it appears to be distinct from the aforementioned SLT CILP (i.e., stage 2b) population that is CD117 + CD161 + CD127 + and that can generate all ILCs including NK cells (42) . Rather, the immunophenotype of the NKP described in the study by Renoux et al. appears to overlap with that of the stage 1 and stage 2a populations described above. Indeed, it will be important in future studies to determine how these various HPC populations are related. Regardless, the study by Renoux et al. raises the intriguing possibility of other NK cell developmental pathways in humans.
It is also important to note that the human model of NK cell development depicted here differs from contemporary models of murine NK cell development (Figure 2) (1, 7, 12) . Aside from inherent challenges in comparing these developmental processes due to differences in species-specific antigen expression, there may be fundamental differences between the species with regards to the developmental relationship(s) between NK cells and other ILCs and with regards to transcription factor expression patterns. For example, in mice, all ILC subsets are thought to derive from a CILP population that subsequently gives rise to committed NKPs as well as to common helper ILC progenitor cells (CHILPs) that can differentiate into ILC1s, ILC2s, and ILC3s, but not NK cells (66) (67) (68) (69) (70) . While putative human CILPs (SLT stage 2b cells) and NKPs have been described as discussed above (42, 65) , it is not yet clear if these two populations are related in the same way that the analogous populations in mice have been described. In addition, a human CHILP population has not been identified.
Another potential difference between mouse and human NK cell development relates to the relationship between NK cells and ILC3s. In mice, these two ILC subsets appear to be developmentally distinct (6) , because in addition to these CHILP data described above, genetic fate-mapping (fm) studies for Rorc2, which encodes Rorγt, showed that mouse ILC3s (19, 20) , and so excluding any CD127 + cells as potential NK cell precursors may be incorrect. Thus, to the best of our knowledge, there is as yet no reliable immunophenotypic strategy to distinguish human stage 3 NK cell precursors from ILC3s. Further investigation is needed.
cONcLUDiNG reMArKs AND FUtUre DirectiONs
The goals of investigating human NK cell development are to understand malignant counterparts and to facilitate the design and implementation of optimal immunotherapies for patients with cancer and potentially other diseases. Much progress has been made; however, the recent discovery of non-NK ILCs has required a reassessment of models of NK cell development in both mice and humans. More work is also needed in order to understand how all ILCs develop and to determine if the putative pathway of human NK cell development in SLTs is representative of NK cell development in other tissues.
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